IMPORTANT SAFETY INFORMATION AND INDICATION
Scroll for Important Safety Information and Indication
IMPORTANT SAFETY INFORMATION
Severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 13® or any diphtheria toxoid–containing vaccine is a contraindication
Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response
In adults, the most commonly reported solicited adverse reactions were pain, redness, and swelling at the injection site, limitation of arm movement, fatigue, headache, muscle pain, joint pain, decreased appetite, vomiting, fever, chills, and rash
In adults 18 years of age and older, Prevnar 13® is indicated for active immunization for the prevention of pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F
Limitations of Use and Effectiveness
- Prevnar 13® will only help protect against S. pneumoniae serotypes in the vaccine
Patients should always ask their doctors for medical advice about adverse events. You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call This website is neither owned nor controlled by Pfizer. Pfizer does not endorse and is not responsible for the content or services of this site.
Please see full Prescribing Information for Prevnar 13®.
Manufactured by Wyeth Pharmaceuticals LLC
© 2020 Pfizer Inc.
All rights reserved.
Marketed by Pfizer Inc.